Our Funders
ACT is proud to be supported by key funders, including Cure Leukaemia, Anthony Nolan, and NHS Blood and Transplant (NHSBT), who play a vital role in advancing research and improving patient outcomes.
Cure Leukaemia
Cure Leukaemia is a UK-based charity dedicated to funding and supporting clinical research into leukaemia and other blood cancers. It collaborates with a wide range of stakeholders, including patients, healthcare professionals, and the TAP and IMPACT clinical trials networks, to accelerate the development of new treatments and improve outcomes for blood cancer patients globally.
ACT is proud to partner with Cure Leukaemia, alongside Anthony Nolan and NHSBT, to expand the capacity for clinical research in the UK.
Cure Leukaemia plays a vital role in supporting clinical trials aimed at improving survival rates for blood cancer patients. The charity works to ensure that funding and resources are directed towards the most promising research projects, ensuring that patients have access to innovative and effective treatments.
Through its partnership with ACT, Cure Leukaemia is committed to driving forward clinical research that addresses critical gaps in treatment, particularly for patient groups who have limited treatment options. The charity is also focused on making sure that its research is inclusive, ensuring that all patients, regardless of background or demographics, benefit from scientific advancements.
Anthony Nolan
Anthony Nolan is a UK stem cell transplant charity with 50 years of expertise in uniting science and people to push the boundaries of what can be achieved for blood cancer and blood disorder patients. Its world-leading stem cell register matches potential donors to patients in need of transplants. It carries out cell and gene therapy research to increase transplant success and supports patients through their transplant journeys.
ACT is proud to partner with Anthony Nolan, Cure Leukaemia, and NHSBT in expanding clinical research capacity in the UK.
For many patients with blood cancers or blood disorders, an allogeneic stem cell transplant is the only curative option. Anthony Nolan was established to match patients with unrelated voluntary stem cell donors. Despite this groundbreaking resource, some patients still face poor outcomes post-transplant. The charity continues to grow the donor register and supports research to improve survival rates and quality of life.
Anthony Nolan is committed to advancing equitable treatment options, particularly for those without fully matched donors. As a founding supporter of the IMPACT trials network, the charity invests in ACT to continue this vital work, ensuring diverse communities are represented in trials.
NHS Blood and Transplant (NHSBT)
NHS Blood and Transplant (NHSBT) is an essential organisation within the UK healthcare system, responsible for the collection, testing, and distribution of blood and organs, as well as managing the UK Stem Cell Registry. NHSBT plays a pivotal role in the treatment of blood cancer patients by facilitating stem cell transplants and other critical procedures, ensuring the availability of life-saving resources to those in need.
ACT is proud to partner with NHSBT, alongside Anthony Nolan and Cure Leukaemia, to enhance clinical research capacity and improve outcomes for blood cancer patients across the UK.
NHSBT supports a broad range of clinical research initiatives, focusing on improving transplant outcomes, increasing donor recruitment, and advancing therapies for blood cancer patients. By collaborating with ACT, NHSBT helps to improve stem cell transplant outcomes through the provision of innovative clinical research.
NHSBT is committed to fostering inclusivity in clinical trials, ensuring that diverse patient populations have access to novel cutting-edge therapies and technologies.
